A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx
A Phase la Trial of Photodynamic Therapy With HPPH (2-1 (Hexyloxyethyl)-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx.
Sponsor: National Cancer Institute (NCI)
A PHASE1 clinical study on Carcinoma of the Oral Cavity and Carcinoma of the Oropharynx, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 9 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE1
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Jun 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Roswell Park Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .